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Thrombolysis for acute ischemic stroke
Karim Hajjar, MD, Daniel M. Kerr, BSc, and Kennedy R. Lees, MD, FRCP, Glasgow, United Kingdom
Thrombolysis with intravenous alteplase is the primary therapy for acute ischemic stroke, and is approved in most
countries. Early administration improves functional outcome though benefit and risk depend on the time elapsed between
stroke onset and initiation of treatment. Randomized controlled trials demonstrated benefit from intravenous throm-
bolysis when initiated up to 4.5 hours after symptom onset, and pooled analysis of all trials indicates that the sooner that
alteplase is given, the greater is the benefit. Treatment carries a risk of bleeding, with symptomatic intracranial
hemorrhage (SICH) of around 3%. Initiating treatment after 4.5 hours increases mortality and reverses the risk-benefit
balance. Baseline stroke severity, age, diabetes and concomitant stroke are associated with poorer outcome from acute
stroke; but secondary analyses and controlled registry data suggest that intravenous alteplase remains effective in most
subgroups. Intra-arterial thrombolysis has a less extensive evidence base and is mostly unapproved for acute stroke. Access
to thrombolysis remains patchy and involves unacceptable delays: greater awareness of the benefits and time dependency
are crucial. ( J Vasc Surg 2011;54:901-7.)
s
o
u
S
s
n
d
H
a
r
u
R
t
t
l
2
(
A
(
I
i
A
l
t
t
t
L
a
cFifteen million people annually will suffer a stroke. Six
million will die and half of survivors become permanently
disabled1: treatment to limit disability is a priority. Eighty-
five percent of strokes are ischemic,2 and early restoration
of blood flow improves outcome in these patients. This
article summarizes current evidence for thrombolysis in
acute ischemic stroke.
METHODS
A systematic search of the MEDLINE database was
performed to identify studies that evaluated efficacy and
safety of thrombolysis in acute ischemic stroke. The studies
considered for the review were randomized controlled
studies (RCTs), pooled-analyses of RCTs, and meta-
analyses on RCT results. Stroke registry data on efficacy and
safety were also considered as supplementary. We excluded
studies to investigate agents or doses that are not currently
in clinical use or under investigation for thrombolysis in
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The main measures of functional clinical outcome
sed for stroke thrombolysis are the modified Rankin
cale (mRS; see Table III for explanation), serious/
ymptomatic intracranial hemorrhage (SICH; intracra-
ial bleeding due to thrombolysis that causes clinical
eterioration), and mortality. The National Institutes of
ealth Stroke Scale (NIHSS; see Table IV for explanation) is
measure of neurological deficit, and the Barthel-Index (BI)
ecords activities of daily living.Outcome is usuallymonitored
ntil 90 days after stroke onset, hence “mRS at 90 days.”
ESULTS
The review considers 11 RCTs on intravenous
hrombolysis (IVT) and three RCTs on intra-arterial
hrombolysis (IAT): two National Institute of Neuro-
ogical Disorders and Stroke (NINDS) trials (part 1 and
),3 three European Cooperative Acute Stroke Study
ECASS) trials,4-6 two Alteplase ThromboLysis for
cute Noninterventional Therapy in Ischemic Stroke
ATLANTIS) trials (part A and B),7,8 and the EchoPlanar
maging THrombolytic Evaluation Trial (EPITHET)9 for
ntravenous thrombolysis with alteplase; twoDesmoteplase in
cute Ischemic Stroke (DIAS) trials10,11 and the Dose Esca-
ation of Desmoteplase for Acute Ischemic Stroke (DEDAS)
rial12 for intravenous thrombolysis with desmoteplase; and
woPROlyse inAcuteCerebralThromboembolism(PROACT)
rials13,14 and the Middle Cerebral Artery Embolism
ocal Fibrinolytic Intervention Trial (MELT)15 for intra-
rterial thrombolysis with urokinase/pro-urokinase. Also
onsidered were results from pooled analyses on RCT inves-
igating IVT16,17 or “mismatch-based” IVT18 and on IAT.19
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September 2011902 Hajjar et alMismatch-based trials are those that selected patients for treat-
ment based on imaging evidence of a mismatch between
established tissue damage (from magnetic resonance [MR]
diffusion sequences) and at-risk tissue (from MR perfusion
sequences): tissue in the mismatch zone is postulated to
remain salvageable at the time of imaging. Supporting data
from the Safe Implementation of Thrombolysis in Stroke
(SITS) register on treatment effects due to extension of the
time window,20 published experience of stroke centers,21 and
baseline clinical factors22 as well as a controlled comparison of
data from the SITS register with the Virtual International
Stroke Trials Archive (VISTA)23-25 were also relevant.
Intravenous thrombolysis. There are eight relevant
RCTs on efficacy and safety of intravenous thrombolysis
(IVT) with alteplase in ischemic stroke (Table I).
Clear evidence of favorable clinical outcome with alte-
plase treatment derives from the NINDS3 and third
ECASS6 trials. Functional outcome at 90 days was signifi-
cantly improved by treatment within 3 hours and between
3 and 4.5 hours of stroke onset (onset to treatment time,
Table I. Results from randomized controlled trials on intr
outcome endpoints, mortality, and symptomatic intracrani
Trial (year of
publication)
Number of Participants
(alteplase/placebo) OTT
Prima
ECASS4
(1995)
620 (313/307) 0-6 h Median m
3 vs 3;
Median B
85 vs 7
NINDS3
(1995)
624 (312/312) 0-3 h Global O
outc
Part 1: 291 (144/147). Part 1: 2.
Part 2: 333 (168/165) Part 2: 1.
ECASS-II5
(1998)
800 (409/391) 0-6 h mRS 0-1
165 (4
.277
ATLANTIS A7
(2000)
142 (71/71) 0-6 h (only
15%  3h)
NIHSS im
at 24
29 (40%)
NIHSS im
at 30
P 
ATLANTIS B8
(1999)
613 (307/306) 3-5 h NIHSS 0
106 (3
.89
ECASS-III6
(2008)
821 (418/403) 3-4.5 h mRS 0-1
219 (5
.04
EPITHET9
(2008)
101 (52/49) 3-6 h mRS 0-1
15/42
.153
ATLANTIS, Acute Noninterventional Therapy in Ischemic Stroke; BI, Barth
modified Rankin Scale;NIHSS,National Institutes of Stroke Scale;NINDS,
odds ratio; OTT, onset from symptoms to treatment time; SICH, symptom
All results intention to treat.
ECASS-II did not quote a P value for differences in SICH.
EPITHET: Functional outcome (mRS 0-1 at 90 days) was not a primary end
mismatch. No P value for SICH quoted.
aAll intracranial hemorrhage.OTT), respectively.3,6 SICH rates were increased after llteplase in both trials, but neither trial identified a signifi-
ant influence on mortality.
The remaining trials are best interpreted by consid-
ring their statistical power in relation to their selection
riteria, especially the delay from stroke onset to treat-
ent. Briefly, the two earlier ECASS trials had a wider
ime window for enrollment, up to 6 hours from stroke
nset, and each demonstrated a strong trend in favor of
reatment.4,5 Similarly, the ATLANTIS trials random-
zed patients up to 6 hours from onset and confirmed a
enefit of treatment when given within 3 hours but not
eyond.26 EPITHET was a pilot trial that included
atients up to 6 hours from stroke onset, primarily
nvestigating imaging measures.9
Pooled analyses of the RCTs16,20 have examined the
nfluence of OTT on benefit and risk of intravenous
lteplase. The odds for excellent outcome (mRS 0-1 at
0 days) with alteplase treatment decrease as OTT in-
reases, with no statistically significant benefit of alte-
lase treatment demonstrated beyond 4.5 hours. Risk of
ous thrombolysis with alteplase regarding primary
morrhage
dpoint (alteplase vs
placebo)
Mortality at 90 Days
(alteplase vs placebo)
SICH
(alteplase vs placebo)
t 90 d:
41
0 d:
.99
69 (22.4%) vs
48 (15.8%); P 
.04
134 (42.8%) vs
113 (36.8%); NSa
good functional 54 (17%) vs
64 (21%); P 
.30
20 (6.4%) vs
2 (0.6%); P 
.001
3-3.2); P  .001
2-2.6); P  .008
d:
vs 143 (36.6%); P 
43 (10.5%) Vs
42 (10.7%); P 
.816
36 (8.8%) vs
13 (3.4%)
ement of 4 points
(21%); P  .02
ement of 4 points
(60%) vs 53 (75%);
16 (22.5%) vs
5 (7%); P  .009
8 (11.3%) vs 0;
P  .003
90d:
vs 104 (34.0%); P 
23 (7.6%) vs
13 (4.2%); P 
.08
21 (6.7%) vs
4 (1.3%); P 
.001
d:
vs 182 (45.2%); P 
32 (7.7%) vs
34 (8.4%); P 
.68
10 (2.4%) vs
1 (0.2%); P 
.008
d:
) vs 9/43 (21%); P 
13/51 (25%) vs
7/49 (14%); P 
.161
4/52 (7.7%) vs 0
ex; ECASS, European Cooperative Acute Stroke Study; EPITHET, ;mRS,
nal Institute of Neurological Disorders and Stroke;NS, not significant;OR,
tracranial hemorrhage.
The mRS results only refer to the population with a computed tomographyaven
al he
ry En
RS a
P  .
I at 9
5; P 
R for
ome:
1 (1.
7 (1.
at 90
0.3%)
prov
h:
vs 15
prov
d: 43
.05
-1 at
4.5%)
at 90
2.4%)
at 90
(36%
.
el Ind
Natio
atic in
point.arge SICH increases with alteplase treatment, appar-
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Volume 54, Number 3 Hajjar et al 903Fig 1. Relation of onset to treatment delay with treatment effect, based on results from eight RCTs. Relation of stroke onset to
start of treatment (OTT) with treatment effect after adjustment for prognostic variables assessed by (A) day 90 modified Rankin
score 0–1 versus 2–6; (B)global test that incorporatesmodifiedRankin score 0–1 versus 2–6, Barthel Index score 95–100 versus
90 or lower and NIHSS score 0–1 versus 2 or more; (C)mortality; and (D) parenchymal hemorrhage type 2 (large intracranial
hemorrhage).Thus, forparenchymalhemorrhage type2, thefitted line isnot statisticallydistinguishable fromahorizontal line.For
eachgraph, the adjustedodds ratio (OR) is shownwith the95%ORofexcellentoutcomes (mRS0-1) at90days: 0-90min2.55
(1.44-4.52); 91-180 min  1.64 (1.12-2.40); 181- 270 min  1.34 (1.06-1.68); 271-360 min  1.22 (0.92- 1.61); 0-360
min  1.40 (1.20- 1.63) OR for mortality with alteplase treatment increases with time. OR for hemorrhagic
complications shows no clear trend with time. Reproduced with permission from Lees et al17 and The Lancet.Table II. Efficacy and safety of the extended time window for thrombolysis within 3 to 4.5 hours OTT
Within 3 hours
Within 3 to 4.5
hours Unadjusted results Adjusted results
N Number (%) N Number (%)
Odds ratio (95%
confidence interval) P
Odds ratio (95%
confidence interval) P
Symptomatic intracerebral
hemorrhage
According to SITS-MOST
definition
21204 352 (1.7%) 2317 52 (2.2%) 1.26 (1.01-1.83) .04 1.44 (1.05-1.97) .02
According to ECASS II definition 21206 1020 (4.8%) 2304 121 (5.3%) 1.10 (0.90-1.33) .35 1.27 (1.03-1.55) .02
According to NINDS definition 21245 1515 (7.1%) 2317 171 (7.4%) 1.04 (0.88-1.22) .66 1.18 (0.99-1.41) .06
Mortality at 3 months 18583 2287 (12.3%) 1817 21 (12.0%) 0.97 (0.84-1.13) .70 1.26 (1.07-1.49) .005
Mortality at 7 days 20956 1307 (6.2%) 2259 132 (5.8%) 0.93 (0.78-1.12) .46 1.22 (1.00-1.48) .052
Functionally independent at 3
months (mRS 0-2)
18317 10531 (57.5%) 1784 1075 (60.3%) 1.12 (1.02-1.24) .02 0.84 (0.75-0.95) .005
Minimal or no disability at 3
months (mRS 0-1)
18317 7467 (40.8%) 1784 793 (44.5%) 1.16 (1.05-1.28) .003 0.92 (0.83-1.03) .17
ECASS, European Cooperative Acute Stroke Study;NIHSS,National Institutes of Health Stroke Scale;NINDS,National Institute of Neurological Disorders
and Stroke; OTT, onset from symptoms to treatment time; SITS-ISTR, Safe Implementation of Treatment in Stroke - International Stroke Thrombolysis
Registry; SITS-MOST, Safe Implementation of Thrombolysis in Stroke - MOnitoring STudy.
Data from SITS-ISTR observational study. Comparison of patients treated with alteplase 0 to 3 hours OTT with patients treated with alteplase 3 to 4.5 hours OTT.
Onunadjustedanalysis, patients treated3.0 to4.5hours afteronsetof symptomsappear tohave reducedmortality andbetter functionaloutcomes.Patients treated in this time
period were younger, with a lower median NIHSS than those treated 0 to 3.0 hours after onset of symptoms. Adjusted analysis shows early treatment is best.
Reproduced with permission from Wahlgren et al20 and The Lancet Neurology.
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September 2011904 Hajjar et alently independent of OTT, though power to test this
interaction is low. Odds for mortality increase with OTT,
reaching statistical significance beyond 4.5 hours OTT
(Fig 1).
The International Stroke Thrombolysis Registry
(SITS-ISTR) observational study20 compared 2376 pa-
tients treated with alteplase within 3 to 4.5 hours OTT
with 23,942 patients who were treated within 0 to 3
hours OTT. Functional outcome was superior in patients
treated within 0 to 3 hours OTT. No significant differ-
ences regarding SICH rates were seen between the 0 to 3
hours cohort and the 3 to 4.5 hours cohort (Table II).
Registry data from over 30,000 patients confirm that
outcomes in routine practice parallel those anticipated from
the RCT.21,22,27
Selection criteria. Careful selection of patients for
IVT appears important, particularly in relation to SICH
risk. From the pooled analysis of RCT, we have reliable
evidence on OTT but have only secondary evidence on
the use of imaging to replace OTT, on the very elderly
and on history of prior stroke with concomitant diabetes.
A subgroup analysis of the NINDS trials28 and a pooled
analysis of observational data from the Stroke-Acute
Ischemic NXY Treatment (SAINT) trials29 suggest that
Table III. The modified Rankin Scale (mRS)
The mRS is the most prevalent outcome measurement in clinical
stroke trials. It categorizes the degree of disability and
dependence in daily activities of patients who suffered from a
stroke on a scale running from 0 to 6, based on an interview
with the patient or caregiver. Although it is an ordinal scale in
which each transition is clinically important, until now most
trials have reported results in a dichotomized manner,
declaring mRS cores of 0 or 1 to represent “excellent
outcome.”
Score Description
0 No symptoms at all.
1 No significant disability despite symptoms, able to carry out
all previous activities.
2 Slight disability, unable to carry out all previous activities, no
assistance needed.
3 Moderate disability, some help required, but able to walk
without assistance.
4 Moderately severe disability, unable to walk without
assistance, unable to attend own bodily needs without
assistance.
5 Severe disability, bedridden, incontinent, requiring constant
care and attention.
6 Death.
Table IV. The National Institutes of Health Stroke Scale
(NIHSS)
The NIHSS is a standardized assessment of neurological
impairment that reflects the severity of the acute stroke deficit.
It comprises 11 subitems measuring various domains of brain
function, assigning a score from 0 to 4 on most items. These
subscores are summed to create a total NIHSS that ranges
from 0 (no impairment) to 42 (maximum impairment).extensive early computed tomography (CT) changes Tedema or mass effect on baseline CT) are associated
ith higher risk of SICH. A multivariable but uncon-
rolled analysis from the Safe Implementation of Throm-
olysis in Stroke Monitoring Study (SITS-MOST)22
eported clinical outcome of stroke to be worse in pa-
ients with increasing age, severe stroke, and comorbidi-
ies. However, controlled comparisons of data from the
nternational Stroke Thrombolysis Registry (SITS-
STR) and the Virtual International Stroke Trials Ar-
hive (VISTA) indicate that alteplase treatment signifi-
antly improves clinical outcome regardless of age (Fig
), across most baseline NIHSS scores, or in patients
ith diabetes and prior stroke.23-25 For functional out-
ome, alteplase did not interact with age (P  .45),
aseline NIHSS (P  .65), diabetes (P  .49), prior
troke (P  .72), or the combination of diabetes and
rior stroke (P  .8).
Mismatch criteria. The diminishing benefit and
ossible increase in risk with delayed OTT, especially
eyond 4.5 hours, have led to investigation of strategies
o identify patients in whom late treatment may remain
afe and beneficial. Four RCTs (DIAS trials I and II,
EDAS trial, EPITHET trial) have incorporated mag-
etic resonance imaging (MRI) perfusion/diffusion mis-
atch to select patients for thrombolysis within an ex-
ended time window.9-12 The two DIAS and the DEDAS
rials used desmoteplase, an investigational thrombolytic
gent with dose not yet defined for stroke treatment, for
VT. This strategy of mismatch-based selection remains
nvestigational since a meta-analysis of randomized data
as not confirmed significant benefit outweighing poten-
ial harm, and results are confounded by the use of
esmoteplase. The odds for excellent outcome at an
verage time to treatment of just over 6 hours were 1.43
95% confidence interval [CI] .87-2.33), with odds for
ICH of 5.37 (95% CI .91-31.8) and for mortality of
.61 (95% CI .71, 3.65).18
Intra-arterial thrombolysis. A small number of
CTs have investigated efficacy and safety of IAT admin-
stered within 6 hours OTT in acute ischemic stroke.
ntra-arterial thrombolysis is believed to achieve higher
ecanalization rates than intravenous delivery. The PRO-
CT-I trial found superior recanalization of the middle
erebral artery (MCA) from IAT with pro-urokinase plus
eparin compared to heparin alone13. The subsequent
ROACT-II trial found favorable clinical outcome (mRS
-2 at 90 days) significantly improved.14 Similar findings
esulted from the MELT trial using IA urokinase, al-
hough they did not reach statistical significance.15 A
eta-analysis of all three RCTs on IAT found signifi-
antly higher rates of overall excellent outcome (mRS
-1) with IAT compared with control patients.19 The
isk of SICH was increased in IAT compared with con-
rol. Mortality rates did not differ significantly between
AT and control (Fig 3). The benefit of IAT has not yet
een compared to IVT in controlled trials; the on-going
andomized controlled Intra-Arterial Versus Systemic
hrombolysis for Acute Ischemic Stroke (SYNTHESIS)
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hours with IAT within 6 hours will be informative.
DISCUSSION
IVT with alteplase in acute ischemic stroke significantly im-
proves outcomewhen administered within 4.5 hours after onset
of symptoms. Benefit of thrombolysis appears to be maintained
in the very elderly, across the range of stroke severity up to
NIHSS of 24, and in patients suffering from diabetes with con-
comitant prior stroke. Benefit decreases with treatment delay;
and at OTT beyond 4.5 hours, mortality rates increase. When
initiated beyond 4.5 hours OTT, the risks of IVT outweigh its
benefits.Sophisticatedselection for IVTusingmismatch imaging
to replace OTT remains investigational. At present, for throm-
bolysis in ischemic stroke only intravenous alteplase is licensed in
most countries, whereas urokinase, pro-urokinase, and desmote-
plase are investigational. Intra-arterial thrombolysis formoderate
or severe stroke up to 6 hours OTTmay be justified as off-label
treatment in specialized centers but is generally unapproved.The
benefits of thrombolysis are largely on functional outcomes. A
significant benefit of thrombolysis on 3-monthmortality has not
so far been confirmed.
From the pooled analysis of 3670 patients from 8 RCTs
Fig 2. Effect of age on benefit of thrombolysis. Cont
Implementation of Treatment in Stroke - Internation
thrombolysed controls from the Virtual International S
patients aged over 80, but the benefit of treatment w
permission from Lees et al23 and British Medical Journausing IV alteplase, there is no doubt of the effectiveness and Occeptable risk/benefit balance for acute ischemic stroke.
hus, thrombolysis with alteplase is presently recognized as
he standard of care for acute ischemic stroke presenting
ithin 4.5 hours OTT. Although effective, it is not a panacea.
pproximately one in three patients treated within 3 hours
TT and one in six patients treated between 3 and 4.5 hours
TT achieve significant benefit.30 This time-dependency of
he risk/benefit balance is crucial, not just the outer limit of
he OTT window that presently appears to be 4.5 hours.
mprovements in stroke services are needed tominimize treat-
ent delays and to make early thrombolysis available to more
atients.
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